Increased SUMO-1 expression in the unilateral rotenone-lesioned mouse model of Parkinson's disease

Neuroscience Letters

Volumn 544, Issue , 2013, Pages 119-124

  Weetman, J ^a   Wong, M B ^a   Sharry, S ^a   Rcom H'cheo Gauthier, A ^a   Gai, W P ^b   Meedeniya, A ^a   Pountney, D L ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Synuclein; Parkinson's disease; Rotenone; SUMO

Indexed keywords

ALPHA SYNUCLEIN; ROTENONE; SUMO 1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRADYKINESIA; BRAIN DAMAGE; BRAIN HOMOGENATE; CONTROLLED STUDY; FOREBRAIN; GROUPS BY AGE; HEMISPHERE; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREMOR;

AGING; ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; PARKINSONIAN DISORDERS; ROTENONE; SUMO-1 PROTEIN; UP-REGULATION;

EID: 84878408246     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.03.057     Document Type: Article

References (28)

1. Anderson D., Wilkinson K., Henley J. Looking ahead: sumoylation in neuropathological conditions. Drug News Perspect. 2009, 22:10.
2. Archibald N., Burn D. Movement disorders: Parkinson's disease. Medicine (Baltimore) 2008, 36:630-635.
3. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
4. Braak H., Bohl J.R., Muller C.M., Rub U., de Vos R.A.I., Tredicic K.D. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 2006, 21:2042-2051.
5. Brown R.C., Lockwood A.H., Sonawane B.R. Neurodegenerative diseases: an overview of environmental risk factors. Environ. Health Perspect. 2005, 113:5.
6. Degli E. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim. Biophys. Acta 1998, 1364:222-235.
7. Deng Y., Newman B., Dunne M.P., Silburn P.A., Mellick G.D. Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. Ann. Neurol. 2004, 55:897.
8. Dobson M. Protein folding and misfolding. Nature 2003, 426:884-890.
9. Dorsey E., Constantinescu R., Thompson J., Biglan K., Holloway R., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson's disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
10. Dorval V., Fraser P. Small unbiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein. J. Biol. Chem. 2006, 281:9919-9924.
11. Gratton A., Wise R. Mapping of contraversive and ipsiversive circling responses to ventral tegmental and Substantia Nigra electrical stimulation. Physiol. Behav. 1985, 35:61-65.
12. Klockgether T. Parkinson's disease: clinical aspects. Cell Tissue Res. 2004, 318:115-120.
13. Krumova P., Meulmeester E., Garrido M., Tirard M., Hsiao H.H., Bossis G., Urlaub H., Zweckstetter M., Kügler S., Melchior F., Bähr M., Weishaupt J.H. Sumoylation inhibits alpha-synuclein aggregation and toxicity. J. Cell Biol. 2011, 194:49-60.
14. Lee Y.J., Mou Y., Maric D., Klimanis D., Auh S., Hallenbeck J.M. Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS ONE 2011, 6:e25852.
15. Lees A. The bare essentials: Parkinson's disease. Pract. Neurol. 2010, 10:240-246.
16. Licker V., Kovari E., Hochstrasser D.F., Burkhard P. Proteomics in human Parkinson's disease research. J. Proteomics 2009, 73:10-29.
17. Lim K. Ubiquitin-proteasome system dysfunction in Parkinson's disease: current evidence and controversies. Expert Rev. Proteomics 2007, 4(6):769-781.
18. Meredith G.E., Sonsalla P.K., Chesselet M. Animal models of Parkinson's disease progression. Acta Neuropathol. (Berl.) 2008, 115:385-398.
19. Norazit A., Meedeniya A.C.B., Nguyen M.N., Mackay-Sim A. Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle. Brain Res. 2010, 1360:119-129.
20. Pountney D., Chegini F., Shen X., Blumbergs P. SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy. Neurosci. Lett. 2005, 381:74-79.
21. Pountney D., Huang Y., Burns R., Haan E., Thompson R., Blumbergs P., Gai W. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp. Neurol. 2003, 184:436-446.
22. Robinson P. Review: Protein stability and aggregation in Parkinson's disease. Biochem. J. 2008, 413:1-13.
23. Schwartz D., Hochstrasser M. A superfamily of protein tags: ubiquitin, SUMO and related modifiers. Trends Biochem. Sci. 2003, 28:321-328.
24. Sherer T.B., Kim J.H., Betarbet R., Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 2003, 179:9-16.
25. Tanner C. The role of environmental toxins in the aetiology of Parkinson's disease. Trends Neurosci. 1989, 12:49-54.
26. Thomas B., Beal M. Parkinson's disease. Hum. Mol. Genet. 2007, 16(spec 2):183-194.
27. Vila M., Jackson-Lewis V., Guegan C., Wu D., Teismann P., Choi D., Tieu K., Przedborski S. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 2001, 14:483-489.
28. Wong M.B., Goodwin J., Norazit A., Meedeniya A.C., Richter-Landsberg C., Gai W.P., Pountney D.L. SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases. Neurotox. Res. 2013, 23(1):1-21.